Gli inibitori dell'enzima di conversione dell'angiotensina: da farmaci vasoattivi a strumento di prevenzione cardiovascolare.

Translated title of the contribution: Angiotensin-converting enzyme inhibitors: from vasoactive drugs to cardiovascular prevention tools

Pietro Amedeo Modesti, Simone Vanni, Gian Franco Gensini

Research output: Contribution to journalArticlepeer-review

Abstract

Abundant evidence showed that angiotensin-converting enzyme (ACE)-inhibitors reduce long-term cardiovascular morbidity and mortality rates in patients with heart failure and myocardial infarction. More recent studies revealed clinical benefits also in hypertensive patients with comorbidity and lead to an extension of clinical indications. Indeed in patients with severe hypertension differences between drugs are hardly detectable because the risk reduction is mainly related to the control of blood pressure values independent of the type of therapy. Conversely in the presence of comorbid conditions, especially in diabetics, the association of ACE-inhibitors with antihypertensive treatments proved its efficacy in reducing cardiovascular morbidity and mortality so that the role of mechanisms extending beyond blood pressure reduction can be postulated.

Translated title of the contributionAngiotensin-converting enzyme inhibitors: from vasoactive drugs to cardiovascular prevention tools
Original languageItalian
Pages (from-to)623-634
Number of pages12
JournalItalian Heart Journal
Volume4
Issue number8 Suppl
Publication statusPublished - Aug 2003

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Angiotensin-converting enzyme inhibitors: from vasoactive drugs to cardiovascular prevention tools'. Together they form a unique fingerprint.

Cite this